Ernexa Therapeutics to Participate in Virtual Investor Closing Bell Series
Key Highlights
- ➤Ernexa executives to present corporate overview and business outlook October 15 at 4:00 PM ET
- ➤ERNA-101 advancement toward clinical development to be highlighted during investor webcast
- ➤ERNA-101 initially targets ovarian cancer, with potential for multiple solid tumors
Live video webcast with Sanjeev Luther, President and Chief Executive Officer; Dr. Christopher Rohde, developer of the technology underlying Ernexa’s platform and member of Ernexa’s Scientific Advisory Board; and Dr. Robert Pierce, Chief Scientific Officer, on Thursday, October 15th at 4:00 PM ET
CAMBRIDGE, Mass., Oct. 12, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancers, today announced that Sanjeev Luther, President and Chief Executive Officer; Dr. Christopher Rohde, member of Ernexa’s Scientific Advisory Board, and developer of the technology underlying Ernexa’s platform; and Dr. Robert Pierce, Chief Scientific Officer, will participate in the Virtual Investor Closing Bell Series on Thursday, October 15, 2026, at 4:00 PM ET.
Get started
Create a free account to read the full story.